Supernus Announces Record Full Year 2018 Financial Results Read more about Supernus Announces Record Full Year 2018 Financial Results
Supernus to Host Fourth Quarter and Full Year 2018 Earnings Conference Call Read more about Supernus to Host Fourth Quarter and Full Year 2018 Earnings Conference Call
Supernus to Present at the 2019 J.P. Morgan Healthcare Conference Read more about Supernus to Present at the 2019 J.P. Morgan Healthcare Conference
Supernus Announces Positive Results from Phase III Study For SPN-812 in Adolescents with ADHD Read more about Supernus Announces Positive Results from Phase III Study For SPN-812 in Adolescents with ADHD
Supernus Announces FDA Approval of sNDA to Expand Oxtellar XR® Label to Include Monotherapy Read more about Supernus Announces FDA Approval of sNDA to Expand Oxtellar XR® Label to Include Monotherapy
Supernus Announces Positive Results from Two Phase III Studies For SPN-812 in Children with ADHD Read more about Supernus Announces Positive Results from Two Phase III Studies For SPN-812 in Children with ADHD
Supernus Schedules Conference Call to Present Topline Results of Two Phase III Studies for SPN-812 in Children with ADHD Read more about Supernus Schedules Conference Call to Present Topline Results of Two Phase III Studies for SPN-812 in Children with ADHD
Supernus to Present at Three November Healthcare Conferences Read more about Supernus to Present at Three November Healthcare Conferences
Supernus Announces Third Quarter 2018 Financial Results and Record Quarterly Revenue Read more about Supernus Announces Third Quarter 2018 Financial Results and Record Quarterly Revenue
Supernus to Host Third Quarter 2018 Earnings Conference Call Read more about Supernus to Host Third Quarter 2018 Earnings Conference Call